This study concluded that the CD19-CART therapy is not only a viable form of treatment, but also an effective approach to prepare patients with chemorefractory ALL to undergo HSCT (Lee et al. 2015). This evidence concerns the gene CD19 and acute lymphoblastic leukemia.